Medicus Pharma Ltd. Common Stock (MDCX)
Stock · NASDAQ · Health Care
$3.25as of 10/16/2026
Price chart
Active signals
MDCX Signal Track Record
How signals performed across all stocks →What MDCX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 12 | -10.2% | 17% | September 3, 2026 |
| Bollinger Band Breakdown | 8 | -17.2% | 13% | October 8, 2026 |
| Bollinger Band Breakout | 5 | -21.1% | 40% | October 9, 2026 |
| Any 20-session window (baseline) | -17.2% | 22% |
Computed by MarketWall from daily closing prices since September 4, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MDCX
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly kno…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 16
- Website
- medicuspharma.com/
Fundamentals
- 1-day range
- $0.0941$0.1155
- Market cap
- $16.97M
- P/E (trailing)
- —
- P/E (forward)
- -0.21
- EPS (trailing)
- $-1.81
- Dividend yield
- —
- Beta
- -1.30
- Avg. volume
- 93.0K
Forecasts
4 analyst ratings
Medicus Pharma Ltd. Common Stock Competitors
Chosen by industry and closest market cap.
- MDCXMedicus Pharma Ltd. Common Stock$3.25▼ 5.25%Market cap $16.97MP/E —$0.144$2.78
- CYCNCyclerion Therapeutics Inc. Common Stock$3.36▼ 0.15%Market cap $16.67MP/E —$7.19$59.36
- SKYESkye Bioscience Inc. Common Stock$1.55▼ 2.52%Market cap $16.58MP/E —$1.5$13.28
- LPCNLipocine Inc. Common Stock$1.56▼ 7.14%Market cap $17.56MP/E —$1.59$12.37
- CTXRCitius Pharmaceuticals Inc. Common Stock$0.46▲ 0.00%Market cap $17.62MP/E —$0.46$2.19
- BFRIBiofrontera Inc. Common Stock$0.822▼ 2.95%Market cap $16.00MP/E —$0.555$1.66
- NCELNewcelX Ltd. Ordinary Shares$2.5▼ 12.28%Market cap $17.98MP/E —$1.83$18.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MDCX Medicus Pharma Ltd. Common Stock | $16.97M | — | $3.25 | ▼ 5.25% | $0.144$2.78 |
| CYCN Cyclerion Therapeutics Inc. Common Stock | $16.67M | — | $3.36 | ▼ 0.15% | $7.19$59.36 |
| SKYE Skye Bioscience Inc. Common Stock | $16.58M | — | $1.55 | ▼ 2.52% | $1.5$13.28 |
| LPCN Lipocine Inc. Common Stock | $17.56M | — | $1.56 | ▼ 7.14% | $1.59$12.37 |
| CTXR Citius Pharmaceuticals Inc. Common Stock | $17.62M | — | $0.46 | ▲ 0.00% | $0.46$2.19 |
| BFRI Biofrontera Inc. Common Stock | $16.00M | — | $0.822 | ▼ 2.95% | $0.555$1.66 |
| NCEL NewcelX Ltd. Ordinary Shares | $17.98M | — | $2.5 | ▼ 12.28% | $1.83$18.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Friday's after hours session: top gainers and losersChartMill · 10/9/2026
- These stocks are moving in today's pre-market sessionChartMill · 10/9/2026
- Top stock movements in today's session.ChartMill · 10/8/2026
- Let's take a look at the stocks that are in motion in today's session.ChartMill · 10/8/2026
- Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in FinancingYahoo · 10/8/2026
- Traders are paying attention to the gapping stocks in Thursday's session.ChartMill · 10/8/2026
- Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advancesYahoo · 10/8/2026
- Thursday's pre-market session: top gainers and losersChartMill · 10/8/2026
Insider Activity
Insider Actions →- Mehmud Faisal · September 4, 2026 · Grant250.0K
- Mehmud Faisal · September 4, 2026 · Grant1.47M @ $0.1705
- Brennan Edward J. · September 4, 2026 · Grant100.0K
- Brennan Edward J. · September 4, 2026 · Grant588.2K @ $0.1705
- Bonner Carolyn F. · September 4, 2026 · Grant250.0K
- Bonner Carolyn F. · September 4, 2026 · Grant1.47M @ $0.1705
- Bokhari Raza · September 4, 2026 · Grant500.0K
- Bokhari Raza · September 4, 2026 · Grant2.94M @ $0.1705
- Smith Andrew Alasdair · September 4, 2026 · Grant125.0K
- Smith Andrew Alasdair · September 4, 2026 · Grant735.3K @ $0.1705
- Rodgers Cathy McMorris · June 3, 2026 · Grant50.0K
- Raju Ajay · June 3, 2026 · Grant50.0K
- Mehmud Faisal · June 3, 2026 · Grant250.0K
- May Sara R. · June 3, 2026 · Grant50.0K
- Kaiser Larry · June 3, 2026 · Grant50.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 2.32M
- Total value held
- $6.44M
- Institutional holders
- 21
- Unknown1.66M
- Unknown240.1K
- Unknown74.0K
- Unknown51.2K
- Unknown50.6K
- Unknown48.1K
- Unknown40.4K
- Unknown37.3K
- Unknown17.8K
- Unknown15.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Medicus Pharma Files Optimized Phase 2b/3 Protocols for Teverelix
Medicus Pharma has filed a streamlined Phase 2b/3 trial design and an optimized registrational protocol for its Teverelix product with the FDA. The filings are aimed at creating a partner‑ready program for advanced prostate cancer treatment. These submissions represent a development milestone that could affect the company’s future regulatory outlook.
Medicus Pharma Files Optimized Phase 2b/3 Protocols for Teverelix. Medicus Pharma has filed a streamlined Phase 2b/3 trial design and an optimized registrational protocol for its Teverelix product with the FDA. The filings are aimed at creating a partner‑ready program for advanced prostate cancer treatment. These submissions represent a development milestone that could affect the company’s future regulatory outlook.